PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.14%
Negative EBIT growth while CRVO is at 9.49%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-26.14%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-26.43%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-26.52%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-26.52%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.09%
Share count expansion well above CRVO's 0.05%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
0.09%
Diluted share count expanding well above CRVO's 0.05%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-57.07%
Negative OCF growth while CRVO is at 24.56%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-57.72%
Negative FCF growth while CRVO is at 24.56%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13659.85%
Negative 10Y OCF/share CAGR while CRVO stands at 95.34%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
12.78%
Below 50% of CRVO's 95.21%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
32.48%
3Y OCF/share CAGR under 50% of CRVO's 91.42%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
-18544.23%
Negative 10Y net income/share CAGR while CRVO is at 97.34%. Joel Greenblatt sees a major red flag in long-term profit erosion.
7.55%
Below 50% of CRVO's 96.33%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
44.34%
3Y net income/share CAGR 50-75% of CRVO's 79.25%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
1862.49%
10Y equity/share CAGR above 1.5x CRVO's 102.37%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
309.42%
5Y equity/share CAGR above 1.5x CRVO's 102.77%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
-81.93%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-30.47%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-33.19%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
No Data
No Data available this quarter, please select a different quarter.
26.95%
We increase R&D while CRVO cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
24.63%
We expand SG&A while CRVO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.